Speech-Language Pathologists in East Hardwick, VT Accepting Medicare
1 Speech-Language Pathologists found. Showing 1 - 1
 Judith R Dunnan, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 593 Eastern Ave, East Hardwick, VT 05836 Phone: 802-533-2243 |
News Archive
Detecting inflammation in diabetic patients
As well as presenting with high blood glucose, diabetic patients have chronic low-grade inflammation, which can be measured by a range of inflammatory markers such as so-called high-sensitive CRP, TNFa and IL-6 as well as a full blood cell count.
UVA study finds that measurement of breast density better predicts woman's breast cancer risk
A new study from UVA Cancer Center found that adding a measurement of breast density better predicts women's risk for breast cancer. Including breast density as part of risk models for breast cancer could support the development of a personalized risk model to recommend how often a woman should have a mammogram based on her unique risk factors.
UGA researcher receives NIH award for high-risk, high-reward carbohydrate research
The National Institutes of Health has awarded a prestigious EUREKA award to Robert Woods, a professor at the University of Georgia Complex Carbohydrate Research Center, to develop a new method for understanding how antibodies interact with large molecules known as glycans that are a major component of all cell surfaces.
Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection
Gilead Sciences, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.
MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
› Verified 7 days ago